Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

27.40 +0.83 (+3.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Why Weight-Loss Developer Stocks Tumbled on Tuesday
Via The Motley Fool
Topics Government
Exposures Political
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
Via The Motley Fool
3 Monster Stocks in the Making
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Down Nearly 20%: Should You Buy the Dip on Eli Lilly?
Via The Motley Fool
Topics Earnings Government World Trade
Exposures Financial Political Tariff
Earnings Scheduled For April 23, 2025
Via Benzinga
Earnings Preview For Viking Therapeutics
Via Benzinga
How Is The Market Feeling About Viking Therapeutics?
Via Benzinga
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April
Via The Motley Fool
Exposures Product Safety
Why Viking Therapeutics Stock Was Victorious This Week
Via The Motley Fool
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors. 
Via The Motley Fool
Topics World Trade
Exposures Tariff
Is Novo Nordisk Stock a Buy?
Via The Motley Fool
Exposures Product Safety
Where Will Viking Therapeutics Be in 3 Years?
Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years. 
Via The Motley Fool
Topics Bankruptcy
Exposures Financial Legal
1 Beaten-Down Stock to Buy and Hold for 10 Years
Via The Motley Fool
Topics Economy
Exposures Economy
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
Via The Motley Fool
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain
Via The Motley Fool
Why Viking Therapeutics Stock Popped Again Today
Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock. 
Via The Motley Fool
Why Viking Therapeutics Stock Popped Today
2025 is the year we learn whether Viking Therapeutics stock will be a winner. 
Via The Motley Fool
Viking Therapeutics Stock May Struggle After As-Expected Report
Viking Therapeutics stock is trying to push higher as investors attempt to sort out a report that delivered no real news that investors hadn’t already heard. 
Via MarketBeat
Viking Therapeutics Stock Dips After Q1 EPS Miss: Details
Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the report. 
Via Benzinga
A Look At Viking Therapeutics VKTX
While we wait for the earnings report to be posted along with the forward guidance predictions, the chart looks interesting. 
Via Talk Markets
Topics Stocks / Equities
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Via The Motley Fool
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding. 
Via The Motley Fool
2 Stocks Down by 25% or More This Year to Buy and Hold
Via The Motley Fool
Topics Government
Exposures Political
Eli Lilly Stock Rockets On Weight-Loss Pill Progress
Eli Lilly's pill-form weight loss drug cansdidate cleared one of several Phase III hurdles. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Viking Therapeutics Stock Pops But Struggles to Hold Gains
VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington 
Via MarketBeat
Will Pfizer Approach Viking Therapeutics With A Buyout Proposa
Investors are running into Viking Therapeutics this week after an incident of drug-induced liver injury pushed Pfizer into terminating the development of its weight-loss pill. 
Via Talk Markets
Topics Stocks / Equities
Down 71%, Should You Buy the Dip on Viking Therapeutics Stock?
Via The Motley Fool
Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish
Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates. 
Via Stocktwits
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Pfizer bows, but is not entirely out of the GLP-1 race. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback